Low-level, low-impact digital solutions, like those that focus solely on patient education, onboarding, or initial engagement, no longer drive the value pharma really needs. The solutions needed to address challenges that range from providing value beyond drug discovery to creating new commercial models, fall increasingly into the classification of Software as a Medical Device (SaMD).
In this whitepaper, experts from S3 Connected Health, Servier, and other leaders in the field share insights and actionable advice on how to develop and launch SaMD digital health solutions that address pharma’s challenges, including:
- Why SaMD is important for digital health
- The capabilities required, and the best approach for pharma when developing solutions
- Defining the intended use of your product, and how it will influence development
- Choosing where to launch your solution
- Planning your regulatory roadmap
- The potential of platforms to reduce risk and accelerate your time to market
Includes insights and advice from:
- Jim O’Donoghue, President of S3 Connected Health
- Andrew Wright, Owner of H1 Consulting and former Vice President of Digital Medicine at Otsuka Pharmaceutical Companies
- Caroline Beaufour, Project Director at WeHealthTM Digital Medicine, the e-health division of the Servier Group
- Hans-Peter Frank, Founder and CEO of T-S-P Health GmbH, CBO of Artha AG
- Marzena Tabaka, Quality Manager at S3 Connected Health
- Vitaliy Myskov, Mobile and Embedded Solutions Manager at S3 Connected Health
